After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

Neutralizing antibodies (nAbs) are being increasingly used as passive antiviral reagents in
prophylactic and therapeutic modalities and to guide viral vaccine design. In vivo, nAbs can …

Broadly neutralizing antibodies (bnAbs) to the HIV envelope (Env) V2-apex region are
important leads for HIV vaccine design. Most V2-apex bnAbs engage Env with an …

Antibodies have been used to prevent or treat viral infections since the nineteenth century,
but the full potential to use passive immunization for infectious diseases has yet to be …

Uncleaved prefusion-optimized (UFO) design can stabilize diverse HIV-1 envelope
glycoproteins (Envs). Single-component, self-assembling protein nanoparticles (1c-SApNP) …

The success of nucleoside-modified mRNAs in lipid nanoparticles (mRNA-LNP) as COVID-
19 vaccines heralded a new era of vaccine development. For HIV-1, multivalent envelope …

Middle East respiratory syndrome coronavirus (MERS-CoV) is a betacoronavirus that
causes severe respiratory illness in humans. There are no licensed vaccines against MERS …

Germline-targeting (GT) HIV vaccine strategies are predicated on deriving broadly
neutralizing antibodies (bnAbs) through multiple boost immunogens. However, as the …

Pfs230 is essential for Plasmodium falciparum transmission to mosquitoes and is the protein
targeted by the most advanced malaria-transmission-blocking vaccine candidate. Prior …

Broadly neutralizing antibodies (bNAbs) against HIV-1 develop after prolonged virus and
antibody coevolution. Previous studies showed that sequential immunization with a V3 …